Boston Scientific delivered a solid Q1 with 9.4% organic sales growth and adjusted EPS at the high end of guidance, though the company has lowered its full-year outlook due to unexpected headwinds affecting growth trajectories.

• Q1 organic revenue exceeded guidance at 9.4%, with adjusted EPS of $0.80, growing 6%.
• Full-year 2026 organic growth guidance reduced to 6.5–8% from prior expectations, reflecting unanticipated challenges.
• U.S. region showed robust 11% growth, driven by multiple business units; EMEA and Asia Pacific experienced slower and strong growth respectively.
• Growth in segments like Neuromodulation remained strong at 15%, while Urology faced challenges with only 1% growth amid product gaps and market disruptions.
• The company remains committed to strategic investments and innovation, despite near-term headwinds impacting some product categories and regional markets.